Skip to content

Propranolol for a treatment of lymphatic malformation

Propranolol for a treatment of lymphatic malformation - Propranolol study for lymphatic malformation

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000008498
Enrollment
20
Registered
2012-07-24
Start date
2012-07-25
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lymphatic malformation

Interventions

Sponsors

University of Tokyo
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1)They are diagnosed as a lymphatic malformation. 2)They have symptoms of bleeding or pain. 3)They have no indication of surgical treatment and sclerotherapy.

Exclusion criteria

Exclusion criteria: 1) Heart disease 2) Hypotension (Systolic blood pressure < 70mmHg) 3) Bradycardia (Pulse rate <60/min) 4) Asthma 5) Diabetic ketoacidosis,metabolic acidosis 6)idiopathic hypoglycemia,uncontroled diabetes (Blood suger < 60mg/dl) 7)fasted state over one month 8)peripheral circulatory disturbance 9)untreated phenochromocytoma 10)administration of thioridazine 11)administration of rizatriptan benzoate 12)oral use of antihypertensive agent 13)oral use or local injection of adrenal cortical steroid 14)Patient who was considered ineligible by the investigators

Design outcomes

Primary

MeasureTime frame
bleeding and pain

Secondary

MeasureTime frame
(Reduction ratio) Measured by MRI and echo images of lymphatic malformation (Other) Changes in the lymphoid follicles (Safety endpoints) Bradycardia, hypotension, drowsiness, insomnia, rash, diarrhea, difficulty breathing, wheezing, decreased blood glucose

Countries

Japan

Contacts

Public ContactMitsunaga Narushima

University of Tokyo plastic and reconstructive surgery

sancho123jp@yahoo.co.jp03-3815-5411

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026